5results about How to "Improve immunosuppression" patented technology

The invention discloses a bispecific cytokine fusion protein, which comprises an amino acid sequence of a type I cytokine and an amino acid sequence of a type II cytokine, and the amino acid sequence of the type I cytokine and the amino acid sequence of the type II cytokine are directly connected through a connecting peptide or are connected in series or in parallel through a fusion partner and the connecting peptide. Amino acid sequences of type I and type II cytokines are connected in series or in parallel to form the bispecific cytokine fusion protein, and the fusion protein can synergistically activate precursor depleted CD8 + T cells and terminal depleted CD8 + T cells, improve immunosuppression of a solid tumor complex microenvironment and release the potential of tumor immunotherapy. The invention further discloses nucleic acid, a carrier, a cell, a medicine or a medicine composition related to the bispecific cytokine fusion protein. The invention also discloses application of the bispecific cytokine fusion protein in preparation of drugs for treating cancers.

The present disclosure relates to a bispecific antibody capable of specifically binding PVRIG and TIGIT, which can modulate the function of immune cells and can be used as a drug to treat diseases related to immune abnormalities, such as tumors.

This invention belongs to the field of biomedical technology, specifically disclosing an injectable embolic agent, its preparation method, and its application. The embolic agent is a hydrocolloid system containing core-shell structured nanoparticles: the core contains Cu... 2+ Salt and ATOX1 inhibitors, where ATOX1 inhibitors can inhibit copper ion efflux and promote intracellular copper accumulation, and interact with Cu 2+ It synergistically induces copper death in tumor cells; the shell is a thermosensitive block copolymer hydrogel that can interact with Cu. 2+ Coordination bonds are formed, enhancing the stability of nanoparticles, while a sol-gel transition occurs at physiological temperatures, enabling precise vascular embolization; the overall core-shell structure allows for the formation of Cu... 2+ The sustained-release effect of ATOX1 inhibitors was observed. In the VX2 rabbit hepatocellular carcinoma model, this embolization agent significantly improved tumor necrosis rate and reduced metastasis rate compared to traditional iodized oil embolization; it also downregulated hypoxia- and angiogenesis-related factors such as HIF-1α, VEGF, and CD31, inhibited MMP9-mediated tumor invasion and metastasis, and promoted CD8+. + T-cell infiltration effectively improves the tumor immunosuppressive microenvironment after transarterial chemoembolization.

The application discloses application of MSCs culture solution in enhancing paracrine and immunosuppression efficiency, wherein a diplotene protein solution is added into a complete MSCs culture medium, i.e., a DMEM / F12 culture medium containing 10% fetal bovine serum, and the MSCs culture solution is obtained after sufficient mixing, wherein the concentration of the diplotene protein in the MSCs culture solution is 1 mu g / ml-500 mu g / ml, and the MSCs culture solution can significantly improve the proliferation capacity, paracrine capacity and immunosuppression efficiency of MSCs without changing the morphology and basic phenotype of the MSCs, the culture solution additive has simple components, can produce significant effects in a short time (24-48h), has wide application prospects, and is favorable for popularization and application.

The invention discloses an IL-6 pre-stimulated umbilical cord mesenchymal stem cell aggregate preparation method and application, and the method comprises the following steps: using IL-6 to pre-stimulate umbilical cord mesenchymal stem cells to obtain pre-stimulated cells, then adding the pre-stimulated cells into an Aggrewell 400 culture plate for centrifugation, continuing to culture the centrifuged pre-stimulated cells for 12-16 h, and obtaining the IL-6 pre-stimulated umbilical cord mesenchymal stem cell aggregate. The pre-stimulated mesenchymal stem cell aggregate is obtained, and the umbilical cord mesenchymal stem cells are in-vitro cells. The invention provides a method for pre-stimulating an umbilical cord mesenchymal stem cell aggregate by using IL-6, which can improve the expression level of inhibitory factors, inhibit the proliferation ability of human peripheral blood mononuclear cells and inhibit the proliferation ability of human CD4 positive T lymphocytes. Through the spherical three-dimensional aggregate structure formed by mutual adhesion of mesenchymal stem cells, the microenvironment of cells in vivo can be better simulated, the survival rate of transplanted stem cells is increased, the retention time in vivo is prolonged, and the treatment effect is improved.